-
公开(公告)号：US10414741B2
公开(公告)日：2019-09-17
申请号：US14916075
申请日：2014-09-30
发明人： Shri Prakash Dhar Dwivedi , Kumar Kamlesh Singh , Jitendra Maganbhai Gajera , Dinesh Kumar Raikwar , Brij Khera
IPC分类号： C07D295/096
摘要： The present invention relates to an amorphous vortioxetine and salts thereof. In particular, the invention relates to a process for the preparation of an amorphous vortioxetine hydrobromide. Further, the invention also relates to a process for preparation of amorphous vortioxetine free base. The invention also relates to pharmaceutical compositions comprising an amorphous vortioxetine or hydrobromide salt thereof for oral administration for treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD).
-
公开(公告)号：US20160045442A1
公开(公告)日：2016-02-18
申请号：US14826125
申请日：2015-08-13
IPC分类号： A61K9/48 , A61K31/606
CPC分类号： A61K9/4808 , A61K9/2027 , A61K9/2054 , A61K9/2059 , A61K9/2846 , A61K9/4825 , A61K31/606
摘要： The present invention relates to stable pharmaceutical compositions of mesalamine. The composition of the invention is a capsule dosage form filled with a tablet. The invention also relates to process for preparing such compositions. The invention specifically relates to a composition of mesalamine wherein the composition is devoid of any reducing sugar or sugar alcohol.
摘要翻译： 本发明涉及美沙拉嗪稳定的药物组合物。 本发明的组合物是填充有片剂的胶囊剂型。 本发明还涉及制备这种组合物的方法。 本发明具体涉及美沙拉嗪组合物，其中组合物没有任何还原糖或糖醇。
-
公开(公告)号：US09603846B2
公开(公告)日：2017-03-28
申请号：US14950430
申请日：2015-11-24
发明人： Brij Khera , Kumar Kamlesh Singh , Santosh Devidas Diwakar , Sunil Dnyaneshwar Narode , Hiteshkumar Natwarlal Suthar
IPC分类号： A61K31/451 , A61K45/06 , C07D471/04 , A61K31/00
CPC分类号： A61K31/451 , A61K31/00 , A61K45/06 , C07D471/04
摘要： A crystalline Form N-1 of apixaban substantially free from one or more of: 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid; 7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-1-phenyl-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide; or methyl 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylate, relative to apixaban by area percentage of HPLC and having a mean particle size equal to or greater than 100 μm.
-
4.发明申请Method of Preparation of Pitavastatin and Pharmaceutical Acceptable Salts Thereof 审中-公开匹伐他汀及其可接受的盐的制备方法公开(公告)号：US20150152061A1
公开(公告)日：2015-06-04
申请号：US14479575
申请日：2014-09-08
IPC分类号： C07D215/14
CPC分类号： C07D215/14
摘要： The present invention discloses a compound, which is alkali or alkaline earth metal salts of pitavastatin, wherein the alkali or earth metal comprise one or more of magnesium, zinc, potassium, strontium and barium.
摘要翻译： 本发明公开了一种化合物，其是匹伐他汀的碱金属或碱土金属盐，其中碱金属或地球金属包含镁，锌，钾，锶和钡中的一种或多种。
-
公开(公告)号：US20150196518A1
公开(公告)日：2015-07-16
申请号：US14593067
申请日：2015-01-09
IPC分类号： A61K31/196 , A61K9/48
CPC分类号： A61K31/196 , A61K9/2027 , A61K9/2054 , A61K9/2059 , A61K9/2846 , A61K9/4808 , A61K31/606
摘要： The present invention relates to pharmaceutical compositions of mesalamine. The composition of the invention is a capsule dosage form filled with a tablet. The invention also relates to process for preparing such compositions. The invention specifically relates to a composition comprising an effective amount of mesalamine having higher bulk density.
摘要翻译： 本发明涉及美沙拉嗪的药物组合物。 本发明的组合物是填充有片剂的胶囊剂型。 本发明还涉及制备这种组合物的方法。 本发明具体涉及包含有效量的具有较高堆积密度的美沙拉嗪的组合物。
-
6.发明授权Method for preparation of pitavastatin and pharmaceutical acceptable salts thereof 有权匹伐他汀及其药学上可接受的盐的制备方法公开(公告)号：US08829186B2
公开(公告)日：2014-09-09
申请号：US13665932
申请日：2012-11-01
IPC分类号： C07D215/14
CPC分类号： C07D215/14
摘要： The present invention discloses a compound, which is alkali or alkaline earth metal salts of pitavastatin, wherein the alkali or earth metal comprise one or more of magnesium, zinc, potassium, strontium and barium.
摘要翻译： 本发明公开了一种化合物，其是匹伐他汀的碱金属或碱土金属盐，其中碱金属或地球金属包含镁，锌，钾，锶和钡中的一种或多种。
-
公开(公告)号：US10925871B2
公开(公告)日：2021-02-23
申请号：US15121514
申请日：2015-02-25
发明人： Brij Khera , Muthaiyyan Essakimuthu Kannan , Jitendra Rameshchandra Patel , Saurin Mukundbhai Amin
IPC分类号： A61K31/4985 , A61K9/20 , A61K47/12 , A61K9/16
摘要： The present invention relates to stable oral pharmaceutical compositions of sitagliptin base and processes for the preparation thereof.
-
8.发明授权Method of preparation of pitavastatin and pharmaceutical acceptable salts thereof 有权匹伐他汀及其药学上可接受的盐的制备方法公开(公告)号：US09139527B2
公开(公告)日：2015-09-22
申请号：US14479575
申请日：2014-09-08
IPC分类号： C07D215/14
CPC分类号： C07D215/14
摘要： The present invention discloses a compound, which is alkali or alkaline earth metal salts of pitavastatin, wherein the alkali or earth metal comprise one or more of magnesium, zinc, potassium, strontium and barium.
摘要翻译： 本发明公开了一种化合物，其是匹伐他汀的碱金属或碱土金属盐，其中碱金属或地球金属包含镁，锌，钾，锶和钡中的一种或多种。
-
公开(公告)号：US09714225B2
公开(公告)日：2017-07-25
申请号：US15035876
申请日：2014-11-13
发明人： Shriprakash Dhar Dwivedi , Jayprakash Ajitsingh Parihar , Alpeshkumar Pravinchandra Shah , Samir Rameshbhai Gajjar , Brij Khera
IPC分类号： A61K31/55 , C07D223/16
CPC分类号： C07D223/16
摘要： The present invention relates to stable crystalline Form I of lorcaserin hydrochloride of Formula (IA) and processes for its preparation. The invention also relates to processes for the preparation of lorcaserin and pharmaceutically acceptable salts, solvates and hydrates thereof.
-
公开(公告)号：US09351957B2
公开(公告)日：2016-05-31
申请号：US14677110
申请日：2015-04-02
发明人： Brij Khera , Kumar Kamlesh Singh , Santosh Devidas Diwakar , Chetan Jayantibhai Vasava , Anil Kumar Shivprasad Tiwari
IPC分类号： C07D209/48 , A61K31/4035 , A61K9/14 , A61K9/16
CPC分类号： A61K31/4035 , A61K9/14 , A61K9/146 , A61K9/1652 , C07D209/48
摘要： The present invention provides an amorphous form of apremilast and process for preparation thereof. The present invention also provides a pharmaceutical composition comprising an amorphous apremilast and one or more of pharmaceutically acceptable carriers, excipients or diluents used for the treatment of active psoriatic arthritis.
摘要翻译： 本发明提供了一种无定形形式的去甲生物及其制备方法。 本发明还提供了一种药物组合物，其包含无定形去极化物和一种或多种用于治疗活动性牛皮癣关节炎的药学上可接受的载体，赋形剂或稀释剂。
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.015 秒)
